ASMB ASSEMBLY BIOSCIENCES, INC.
Price Chart
Executive Summary
Assembly Biosciences announced plans to expand clinical development of ABI-6250, its oral NTCP inhibitor, from chronic hepatitis delta virus (HDV) into primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). A Phase 2 HDV study is expected in Q4 2026, and a Phase 2 basket study in PBC/PSC is expected in Q1 2027, supported by completed Phase 1a data and a constructive pre-IND meeting with the FDA. This is an early-stage pipeline expansion with no new financial data, and the company's historical filings have underperformed at T+20, warranting a cautious neutral read.
Actionable Insight
This is an early pipeline expansion with no revenue or earnings data. Monitor for FDA feedback on the pre-IND meeting and initiation of Phase 2 studies in late 2026/early 2027. The stock's historical T+20 performance on prior filings has been weak (avg -4.84%), so near-term catalysts are limited.
Key Facts
- ABI-6250 is an oral small-molecule NTCP inhibitor being developed for HDV, PBC, and PSC.
- Phase 1a trial in healthy participants completed; target engagement shown via dose-dependent plasma bile acid elevations.
- Chronic toxicology studies completed, supporting longer-term dosing in Phase 2.
- Phase 2 HDV study planned for Q4 2026; Phase 2 basket study in PBC/PSC expected Q1 2027, subject to regulatory feedback.
- Pre-IND meeting with FDA held; official minutes pending but company describes discussion as constructive.
- No approved therapies exist for PSC; significant unmet need remains in PBC despite available treatments.
- ABI-6250 has not been approved anywhere; safety and efficacy not established.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- ABI-6250 is preclinical for PBC/PSC; clinical failure risk is high.
- No approved therapies for PSC means regulatory path is uncertain.
- Company may need additional capital to fund multiple Phase 2 trials; dilution risk exists.
- Pre-IND meeting minutes pending; FDA could impose additional requirements.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-235469 |
| Document: asmb-ex99_1.htm | 0001193125-26-235469 |
| Document: 0001193125-26-235469-index-headers.html | 0001193125-26-235469 |
| Document: 0001193125-26-235469.txt | 0001193125-26-235469 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
8-K
| $22.89 awaiting T+5 | awaiting T+5 | — | $22.56 (−1.44%) |
|
May 22, 2026
18d ago
|
424B5
| $28.75 $26.92 | ▲ +6.37% | ▲ +7.45% | $22.56 (+21.53%) |
|
May 22, 2026
18d ago
|
8-K
| $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $22.56 (−20.40%) |
|
May 22, 2026
18d ago
|
Press Release
| $28.34 $26.92 | ▼ −5.01% | ▼ −6.67% | $22.56 (−20.40%) |
|
May 7, 2026
4w ago
|
Press Release
| $29.74 $30.30 | ▲ +1.88% | ▲ +0.42% | $22.56 (−24.14%) |
|
Mar 30, 2026
10w ago
|
EFFECT
| $26.64 $28.53 | ▲ +7.09% | ▲ +2.79% | $22.56 (−15.32%) |
|
Mar 19, 2026
11w ago
|
Press Release
| $28.46 $27.70 | ▼ −2.67% | ▼ −0.52% | $22.56 (−20.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access